1. Targeting CD137 enhances vaccine-elicited anti-respiratory syncytial virus CD8+ T cell responses in aged mice.
- Author
-
Lee S, Mittler RS, and Moore ML
- Subjects
- Age Factors, Animals, Antibodies, Monoclonal administration & dosage, Antibodies, Monoclonal pharmacology, CD8-Positive T-Lymphocytes drug effects, Female, Interferon-gamma biosynthesis, Lung drug effects, Lung immunology, Lung metabolism, Lung virology, Mice, Respiratory Syncytial Virus Infections prevention & control, Tumor Necrosis Factor Receptor Superfamily, Member 9 agonists, Vaccination, Antibodies, Monoclonal immunology, CD8-Positive T-Lymphocytes immunology, Respiratory Syncytial Virus Infections immunology, Respiratory Syncytial Virus Vaccines immunology, Respiratory Syncytial Viruses immunology, Tumor Necrosis Factor Receptor Superfamily, Member 9 immunology
- Abstract
Respiratory syncytial virus (RSV) causes significant morbidity and mortality in children and the elderly. No vaccines for RSV are in use. Because of immunosenescence, the immunologic requirements for a successful RSV vaccine in the elderly might differ from a RSV vaccine for young children. Using an aged mouse model of RSV pathogenesis, we found that aged mice had impaired Ag-specific CD8(+) T cell responses and delayed RSV clearance compared with young mice. To study vaccine-elicited RSV-specific CD8(+) T cells in aged mice, we used a peptide vaccine approach. TriVax is a commixture of a peptide representing immunodominant RSV CD8(+) T cell epitope M282-90, a TLR agonist (polyinosinic-polycytidylic acid), and a costimulatory anti-CD40 Ab. TriVax vaccination generated robust, polyfunctional, and protective CD8(+) T cell responses in young BALB/c mice, but not in 18-mo-old (aged) BALB/c mice. We hypothesized that treatment of aged mice with agonistic anti-CD137 (41BB) mAb will partially restore T cell responses and TriVax efficacy in aged mice. We immunized 18-mo-old BALB/c mice twice with TriVax + anti-41BB mAb or TriVax + isotype control Ab. Coadministration of anti-41BB mAb with TriVax enhanced RSV-specific CD8(+) T cell responses and TriVax efficacy in challenge experiments. Triggering the 41BB costimulatory pathway may be a strategy for enhancing T cell responses to vaccines in the elderly.
- Published
- 2014
- Full Text
- View/download PDF